Article
LSD1 acts as an epigenetic barrier against glucocorticoid-induced atrophy and…
medRxiv · 2022 · Araki, H.; Hino, S.; Anan, K.; Kuribayashi, K.; Etoh, K.; Seko, D.; Takase, R.; Kohrogi, K.; Hino, Y.; Ono, Y.; Araki, E.; Nakao, M.
Key facts
| Title | LSD1 acts as an epigenetic barrier against glucocorticoid-induced atrophy and exercise-induced hypertrophy in skeletal muscle |
|---|---|
| First author | Araki, H.; Hino, S.; Anan, K.; Kuribayashi, K.; Etoh, K.; Seko, D.; Takase, R.; Kohrogi, K.; Hino, Y.; Ono, Y.; Araki, E.; Nakao, M. |
| Journal | medRxiv |
| Published | Oct 9, 2022 |
| DOI | 10.1101/2022.10.08.509614 |
| Devices mentioned | BK110039, K103302, K800781 |
| Product codes mentioned | JJX, KIP, KIT, NDS, NJT, OOI, PFF, PFT, KIS, PCA |
At a glance
- 1–9 FDA submissions mentioned
- 10–99 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1